Skip to content
Biodatica
Start free

MODULATION THERAPEUTICS, INC.

MORGANTOWN, WV

OncologyPhase I
Compare Sign in to watch

What changed

Phase I trial registered: MTI-301 for the Treatment of Metastatic or Unresectable and Refractory Solid Cancers

4mo agoTrial registeredMar 19, 2026Source filing (opens the source filing in a new tab)

Momentum

72no change

Momentum 72 out of 100, unchanged since the last recompute.

Accelerating: several high-weight events landed recently.

Runway (estimate)

—unknown

No disclosed raise on file, so there is nothing to model from.

Stage

Phase I

The furthest-along thing in the public record. Not a projection.

Runway is an estimate: the last disclosed raise (SEC Form D) minus a modeled burn rate for the company’s stage and therapeutic area. It is not a disclosure, and companies routinely raise non-dilutive money we can’t see. How this is calculated.

Peer position

551 pre-ticker oncology companies at Phase I

Peer ranking — where this company sits among its stage-and-area peers by momentum, and how its runway compares to the peer median — is part of the Analyst tier.

Compare seats

A ranking of the same momentum figure the feed publishes, computed live against public-filing peers. It is a relative position, not a recommendation, and it is identical for every viewer.

Grant to raise

Every record Biodatica has resolved onto this company, newest first, each linked to the filing it came from. Where a source publishes no stable deep link for a record, the identifier is shown so you can look it up yourself.

  1. Trial

    PHASE1 registered

    Nov 7, 2025

    Metastatic Malignant Solid Neoplasm, Refractory Malignant Solid Neoplasm, Unresectable Malignant Solid Neoplasm · RECRUITING · sponsor: Mayo Clinic · MTI-301 for the Treatment of Metastatic or Unresectable and Refractory Solid Cancers

    ClinicalTrials.gov · NCT06911008 (opens the source filing in a new tab)

  2. Grant

    R44 · $218k · non-dilutive

    Sep 15, 2022

    MODULATION THERAPEUTICS, INC. · PI HAYES, KAREN E · NCI · award ends Aug 31, 2026 · Modulation of cancer induced immune suppression via inhibition of SCD1

    NIH RePORTER · NIH RePORTER 11328609 (opens the source filing in a new tab)

  3. Trial

    Study registered

    May 30, 2013

    Hormone-Resistant Prostate Cancer, Metastatic Prostate Carcinoma, Prostate Adenocarcinoma, Recurrent Prostate Carcinoma · ACTIVE_NOT_RECRUITING · sponsor: Mayo Clinic · Gene Expression in Patients With Metastatic Prostate Cancer Receiving CYP-17 Inhibition Therapy

    ClinicalTrials.gov · NCT01953640 (opens the source filing in a new tab)

Biodatica publishes impersonal research shown identically to every subscriber. This dossier is informational only, it is not investment advice, and the momentum and runway figures are estimates derived from public filings. The underlying records are U.S. government works. Disclosures · Data sources